Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A meta-analysis

Journal of Digestive Diseases

Volumn 14, Issue 8, 2013, Pages 409-416

  Xu, Qi ^a,b   Xu, An Tao ^a   Zhu, Ming Ming ^a   Tong, Jin Lu ^a   Xu, Xi Tao ^a   Ran, Zhi Hua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colorectal neoplasms; Epidermal growth factor receptor; Human BRAF protein; Meta analysis; Monoclonal antibodies; Mutation

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; META ANALYSIS; METASTATIC COLORECTAL CANCER; MUTANT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; WILD TYPE;

COLORECTAL NEOPLASMS; EPIDERMAL GROWTH FACTOR RECEPTOR; HUMAN BRAF PROTEIN; META-ANALYSIS; MONOCLONAL ANTIBODIES; MUTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880022343     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12063     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Cunningham D, Atkin W, Lenz HJ etal. Colorectal cancer. Lancet 2010; 375: 1030-1047.
3. Normanno N, De Luca A, Bianco C etal. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
4. Cunningham D, Humblet Y, Siena S etal. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
5. Van Cutsem E, Peeters M, Siena S etal. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
6. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
7. Qiu LX, Mao C, Zhang J etal. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010; 46: 2781-2787.
8. Lièvre A, Bachet JB, Le Corre D etal. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
9. Di Fiore F, Blanchard F, Charbonnier F etal. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169.
10. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F etal. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-2648.
11. Di Nicolantonio F, Martini M, Molinari F etal. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
12. Molinari F, Martin V, Saletti P etal. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 2009; 100: 1087-1094.
13. Moroni M, Veronese S, Benvenuti S etal. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286.
14. Cappuzzo F, Varella-Garcia M, Finocchiaro G etal. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99: 83-89.
15. Freeman DJ, Juan T, Reiner M etal. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008; 7: 184-190.
16. Loupakis F, Ruzzo A, Cremolini C etal. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721.
17. Perrone F, Lampis A, Orsenigo M etal. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20: 84-90.
18. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M etal. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 2009; 4: e7287.
19. Laurent-Puig P, Cayre A, Manceau G etal. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930.
20. Tol J, Dijkstra JR, Klomp M etal. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46: 1997-2009.
21. Montagut C, Iglesias M, Arumi M etal. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Br J Cancer 2010; 102: 1137-1144.
22. De Roock W, Claes B, Bernasconi D etal. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
23. Van Cutsem E, Köhne CH, Láng I etal. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019.
24. Saridaki Z, Tzardi M, Papadaki C etal. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2nd line cetuximab-based therapy of colorectal cancer patients. PLoS ONE 2011; 6: e15980.
25. Garcia-Albeniz X, Pericay C, Alonso-Espinaco V etal. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumour Biol 2011; 32: 417-424.
26. Fornaro L, Baldi GG, Masi G etal. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. Crit Rev Oncol Hematol 2011; 78: 243-251.
27. Modest DP, Jung A, Moosmann N etal. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer 2012; 131: 980-986.
28. Tveit KM, Guren T, Glimelius B etal. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762.
29. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
30. Mao C, Liao RY, Qiu LX, Wang XW, Ding H, Chen Q. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep 2011; 38: 2219-2223.